Report Overview

Canada NSCLC Drug market size stood at around USD XX billion in 2020 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

In Canada, nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer cases. The highest ASIR of stage IV NSCLC was observed for Nova Scotia (38.5 per 100,000) and the lowest in Ontario (25.5 per 100,000). For stage IV SCLC, the highest ASIR was observed in Nova Scotia (9.0 per 100,000), but the lowest was observed in British Colombia (4.3 per 100,000). This increase, coupled with an anticipated rise in branded therapy prescriptions in Canada, will drive both the Canadian and global NSCLC markets over the forecast period.



Market Drivers

The increasing incidence of NSCLC will drive the growth of this market. The growing incorporation of premium-priced immune checkpoint inhibitor immunotherapies into the NSCLC treatment algorithm, particularly in the first-line setting, will be one primary driver. An increasing number of diagnoses of non-small cell lung cancer and the growing awareness in developed and developing markets are also contributing towards the non-small cell lung cancer drugs market growth. This, coupled with increasing investments by major players in research and development activities and the inclusion of non-small cell cancer drugs in pipelines of significant market players, also boosts the market growth.